News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bayer Yakuhin Ltd. To Transfer Baynas Marketing Rights To Nippon Shinyaku Co., Ltd.



4/24/2006 10:56:52 AM

Tokyo, Apr 24, 2006 (JCN) - Bayer Yakuhin and Nippon Shinyaku have reached an agreement on the sale of Baynas Tablet, Bayer's proprietary anti-allergic rhinitis drug, in Japan. Under the agreement, Bayer Yakuhin will transfer the marketing rights to the agent to Nippon Shinyaku on July 1. Baynas Tablet is an agent that antagonizes prostaglandin D2 and thromboxane A2 receptors, which cause allergic rhinitis. Initially launched in May 2005, sales of the agent reached 3 billion yen ($25.3 mil) in 2005.


Read at JCN Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES